Quantitative Imaging Study of Extent of Surgical Resection and Prognosis of Malignant Astrocytomas

Kowalczuk, Andrew; Rl, Macdonald; Amidei, Chris; Dohrmann, George J.; Rk, Erickson; Hekmatpanah, Javad; Krauss, Stephen; Krishnasamy, Swarna; Masters, Greg; Sf, Mullan; Aj, Mundt; Sweeney, Paul; Ee, Vokes; Bk, Weir; Rl, Wollman

doi:10.1097/00006123-199711000-00004

Cited by 194 publications

(109 citation statements)

References 58 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…As said above, the difference among these two groups is statistically significant (Mantel-Cox P = 0.0275). These observations confirm literature data (Devaux et al, 1993;Iacoangeli et al, 1993;Kowalczuk et al, 1997), and ensure that the tumour population we are dealing with is representative of the general population of patients suffering from brain tumour that are in the conditions of undergoing surgery. When the survival of these patients is stratified according to MnSOD level in the tumour, a strong link of these levels and prognosis can be observed.…”

Section: Mnsod Content Is An Independent Prognostic Factorsupporting

confidence: 88%

The level of manganese superoxide dismutase content is an independent prognostic factor for glioblastoma. Biological mechanisms and clinical implications

et al. 2001

View full text Add to dashboard Cite

SummaryWe address the issue of the role of manganese superoxide dismutase in tumorigenesis by studying a relatively homogeneous group of tumours for the correlation between amount of this anti-oxidant enzyme and prognosis. The clinical outcome of 30 patients affected by glioblastomas whose manganese superoxide dismutase content had been established at the time of first diagnosis is compared. When the survival of patients is stratified according to manganese superoxide dismutase level in the tumour, a link of these levels and prognosis can be observed. Patients with high levels of manganese superoxide dismutase show a median survival time of 6.11 months, while patients whose tumours display a low amount of MnSOD have a median survival time of 12.17 months. To assess the upstream mechanisms that sustain the increase in manganese superoxide dismutase content in brain neuroepithelial tumours, we also studied the expression of p53 in a series of 17 astrocytomas of various grading. In all tested astrocytomas, high manganese superoxide dismutase content is associated with cytoplasmic accumulation of p53. Thus glioblastomas can be divided into two distinct groups on the basis of their content of manganese superoxide dismutase, having 'better' or 'worse' prognosis, respectively. The use of this protein as a marker may help to define therapeutic strategies in the clinical management of glioblastoma.

show abstract

Section: Mnsod Content Is An Independent Prognostic Factorsupporting

confidence: 88%

The level of manganese superoxide dismutase content is an independent prognostic factor for glioblastoma. Biological mechanisms and clinical implications

et al. 2001

View full text Add to dashboard Cite

show abstract

“…Several authors declare that patients with higher KPS showed longer survival rather those with lower KPS. 2,6,8,10,14 According to Kreth et al 9 the youngest individuals tend to show higher KPS, which may be considered a confusing variable in the multivariate statistical analysis models. In Lacroix et al series 10 75% of patients showed KPS higher than 80.…”

Section: Discussionmentioning

confidence: 99%

“…3) Tumor volume -Several papers identify the tumor volume as a non-prognostic factor. 8,9,14,21 On the other hand, Jeremic et al 6 mention that tumors smaller than 40 cm 3 show better prognosis. The average tumor volume in Lacroix et al 10 series was 34 cm 3 .…”

Section: Discussionmentioning

confidence: 99%

“…8,9,16,18 When comparing the patients submitted to total resection versus biopsy, Kreth et al 9 got average survival of 37 and 33 weeks respectively but without any statistic significance. Kowalczuck et al 8 described the resection extension as less important than other factors previously analyzed such as age, the KPS and RT in a retrospective study. The patients submitted to a total resection had a longer survival without getting any statistic significance in our series (p = 0.3).…”

Section: Modifiable Prognostic Factorsmentioning

confidence: 99%

“…2) Radiotherapy -The role of RT in treating glioblastoma has already been established. 1,2,6,8,12,22 Mineo et al 15 mention radiotherapy as the factor with most influence on the prognosis independently of age, the KPS and the surgical extension. According to Barker et al 1 the radiotherapy has more influence in younger patients.…”

Section: Modifiable Prognostic Factorsmentioning

confidence: 99%

See 2 more Smart Citations

Untitled

2010

Arq Bras Neurocir

View full text Add to dashboard Cite

RESUMO Fatores prognósticos no glioblastoma multiforme Objetivo: Observar se os fatores prognósticos dos pacientes com glioblastoma multiforme (GBM), como a idade, o Karnofsky Performance Status (KPS), a extensão da remoção tumoral, a realização de radioterapia e o volume tumoral, influenciam a sobrevida dos pacientes. Método: Realizamos uma revisão retrospectiva dos prontuários dos pacientes operados no Hospital dos Servidores do

show abstract

Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors

Perry

Jenkins

O’Fallon

et al. 1999

Cancer

View full text Add to dashboard Cite

BACKGROUND The biologic behavior of anaplastic (World Health Organization Grade III) astrocytomas and oligoastrocytomas is highly variable, ranging from rapid progression to prolonged survival. It is difficult to predict the outcome of an individual patient based on morphology alone. METHODS To determine the prognostic value of commonly used clinicopathologic markers, we reviewed our experience with 85 similarly treated patients enrolled in 3 North Central Cancer Treatment Group high grade glioma protocols. The pathology was comprised exclusively of primary anaplastic astrocytic tumors (66 astrocytomas and 19 oligoastrocytomas). Variables examined included patient age, morphologic type, preoperative performance score, extent of surgery, solitary versus multiple mitoses, DNA flow cytometric and image morphometric parameters, and expression of proliferating cell nuclear antigen, MIB‐1, and p53 expression. RESULTS The study was comprised of 48 men and 37 women ranging in age from 14–79 years (median age, 47 years). Overall survival ranged from <1 month to >12 years (median, 21.6 months). Statistical analyses revealed that age accounted for the majority of this extensive variability in survival. The median survival times were 65.5 months, 22.1 months, and 4.4 months, respectively, for the groups <40 years, 40–59 years, and ≥60 years, respectively (P < 0.0001). On univariate analyses, aneuploidy by flow cytometry and a low performance score also predicted a better survival (P values of 0.04 and 0.009, respectively). Statistical trends predicting a better survival were observed for patients with a solitary mitosis and p53 immunopositivity. However, only patient age remained significant in multivariate models. CONCLUSIONS In a small but relatively uniformly treated cohort of patients with anaplastic astrocytomas and oligoastrocytomas, patient age was associated strongly and inversely with overall survival. Once patient age was taken into account, the clinical and pathologic markers tested appeared to be of limited prognostic value. Cancer 1999;86:672–83. © 1999 American Cancer Society.

show abstract

Quantitative Imaging Study of Extent of Surgical Resection and Prognosis of Malignant Astrocytomas

Cited by 194 publications

References 58 publications

The level of manganese superoxide dismutase content is an independent prognostic factor for glioblastoma. Biological mechanisms and clinical implications

The level of manganese superoxide dismutase content is an independent prognostic factor for glioblastoma. Biological mechanisms and clinical implications

Untitled

Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors

Contact Info

Product

Resources

About